Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic

Neoplasma

Volumn 55, Issue 2, 2008, Pages 101-106

  Krol, L ^a   Formankova, R ^a   Keslova, P ^a   Vavra, V ^a   Zemanova, Z ^b   Michalova, K ^c   Dobrovolna, M ^c   Moravcova, J ^c   Kobylka, P ^c   Ivaskova, E ^d   Navratilova, J ^e   Stary, J ^a   Sedlacek, P ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d Czech Stem Cells Registry (CSCR)   (Czech Republic)

^e Czech National Marrow Donors Registry   (Czech Republic)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Children; Incidence; Prognosis

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; THIOTEPA; THYMOCYTE ANTIBODY; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRESCHOOL CHILD; PROGNOSIS; RELAPSE; SCHOOL CHILD; TREATMENT OUTCOME; MORTALITY; TIME;

ADOLESCENT; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; TIME FACTORS;

EID: 48549106575     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. CORTES J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 569-84, viii.
2. CLIFT RA, BUCKNER CD, THOMAS ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994; 84: 4368-4373 (Pubitemid 24371944)
3. GARCIA-MANERO G, FADERL S, O'BRIEN S et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 2003; 98: 43-57.
4. VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302
5. FABER E, KOZA V, VITEK A et al. Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic - a retrospective analysis of results in years 1988-2005. Vnitr Lek 2006; 52: 1172-1180
6. PULSIPHER MA. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004; 43: 523-533
7. RADICH JP, OLAVARRIA E, APPERLEY JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 685-702, x.
8. MORAVCOVA J, NADVORNIKOVA S, ZMEKOVA V et al. Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML. Leuk Res 2003; 27: 719-729
9. GIRALT SA, ARORA M, GOLDMAN JM et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467 (Pubitemid 46698285)
10. TALPAZ M, SILVER RT, DRUKER BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937 (Pubitemid 34525471)
11. KANTARJIAN HM, O'BRIEN S, CORTES JE et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167-2176 (Pubitemid 34753587)
12. KANTARJIAN HM, TALPAZ M, O'BRIEN S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177-2187
13. SOVERINI S, IACOBUCCI I, BACCARANI M, MARTINELLI G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007; 92: 437-439
14. COLLINS RH, JR., SHPILBERG O, DROBYSKI WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15: 433-444 (Pubitemid 27074209)
15. PORTER DL, COLLINS RH, JR., HARDY C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221 (Pubitemid 30099829)
16. DAZZI F, SZYDLO RM, CRADDOCK C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
17. NOVITZKY N, RUBINSTEIN R, HALLETT JM et al. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Transplantation 2000; 69: 1358-1363
18. SAVANI BN, MONTERO A, KURLANDER R et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015
19. MILLOT F, GUILHOT J, NELKEN B et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006; 20: 187-192 (Pubitemid 43148651)
20. WEISSER M, TISCHER J, SCHNITTGER S et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91: 663-666